Physiologically based pharmacokinetic model combined with a clinical lactation study to determine doravirine concentrations in human breastmilk

Documenti analoghi

• Pharmacokinetic parameters of bictegravir in breastmilk of healthy, lactating volunteers without HIV after a single dose of 50 mg (co‐formulated with emtricitabine 200 mg and tenofovir alafenamide 25 mg)
  di: L. Van Der Wekken‐Pas, et al.
  Pubblicazione: (2025)
• Population pharmacokinetic analysis of doravirine in real‐world people with HIV
  di: Paul Thoueille, et al.
  Pubblicazione: (2024)
• Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis
  di: Sharon Sawe, et al.
  Pubblicazione: (2025)
• Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics
  di: Qiushi Wang, et al.
  Pubblicazione: (2024)
• Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women
  di: William Saffaf, et al.
  Pubblicazione: (2026)